Alprazolam potentiates the antiaversive effect induced by the activation of 5-HT1A and 5-HT2A receptors in the rat dorsal periaqueductal gray

Psychopharmacology

Volumn 198, Issue 3, 2008, Pages 341-349

  De Bortoli, Valquíria Camin ^a   Nogueira, Regina Lúcia ^b,c   Zangrossi Jr , Hélio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b ESTÁCIO DE SÁ UNIVERSITY   (Brazil)

^c UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

Author keywords

Alprazolam; Panic disorder; Periaqueductal gray matter; Sensitization; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ALPRAZOLAM; MIDAZOLAM; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVERSIVE BEHAVIOR; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; ELECTRIC CURRENT; MALE; MICROINJECTION; NEUROTRANSMISSION; NONHUMAN; PANIC; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT; WISTAR RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ALPRAZOLAM; AMPHETAMINES; ANIMALS; ANTI-ANXIETY AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; MALE; MICROINJECTIONS; PERIAQUEDUCTAL GRAY; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN AGONISTS; SYNAPTIC TRANSMISSION;

EID: 44249099434     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-008-1134-7     Document Type: Article

References (64)

1. Amano K, Tanikawa T, Iseki H, Kawabatake H, Notani M, Kawamura H, Kitamura K (1978) Single neuron analysis of the human midbrain tegmentum. Rostral mecencephalicreticulotomy for pain relief. Appl Neurophysiol 41:66-78
2. American Psychiatry Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn revised. APA Press, Washington, DC
3. Andersch S, Rosenberg NK, Kullingsjo H, Ottosson JO, Bech P, Bruun-Hansen J, Hanson L, Lorentzen K, Mellergard M, Rasmussen S et al (1991) Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatr Scand Suppl 365:18-27
4. Audi EA, Graeff FG (1984) Benzodiazepine receptors in the periaqueductal grey mediate anti-aversive drug action. Eur J Pharmacol 103(3-4):279-285
5. Bakker A, van Balkom AJ, Stein DJ (2005) Evidence-based pharmacotherapy of panic disorder. Int J Neuropsychopharmacol 8(3):473-482
6. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19(6):567-596
7. Ballenger JC, Burrows GD, DuPont RL Jr, Lesser IM, Noyes R Jr, Pecknold JC, Rifkin A, Swinson RP (1988) Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 45(5):413-422
8. Bandler R, Carrive P, Depaulis A (1991) Introduction: emerging principles of organization of the midbrain periaqueductal gray matter. In: Depaulis A, Bandler R (eds) The midbrain periaqueductal gay matter: functional, anatomical and neurochemical organization. Plenun, New York, pp 1-8
9. Benarroch EE (1993) The central autonomic network: functional organization, dysfunction, and perspective. Mayo Clin Proc 68(10):988-1001
10. Bengtsson HJ, Kele J, Johansson J, Hjorth S (2000) Interaction of the antidepressant mirtazapine with alpha2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo. Naunyn Schmiedebergs Arch Pharmacol 362(4-5):406-412
11. Broderick PA (1997) Alprazolam, diazepam, yohimbine, clonidine: in vivo CA1 hippocampal norepinephrine and serotonin release profiles under chloral hydrate anesthesia. Prog Neuropsychopharmacol Biol Psychiatry 21(7):1117-1140
12. Casacalenda N, Boulenger JP (1998) Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications. Can J Psychiatry 43(7):722-730
13. Connor KM, Davidson JRT (1998) Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. Biol Psychiatry 44:1286-1294
14. de Bortoli VC, Nogueira RL, Zangrossi H Jr (2006) Effects of fluoxetine and buspirone on the panicolytic-like response induced by the activation of 5-HT1A and 5-HT2A receptors in the rat dorsal periaqueductal gray. Psychopharmacology (Berl) 183(4):422-428
15. den Boer JA, Slaap BR (1998) Review of current treatment in panic disorder. Int Clin Psychopharmacol 13(suppl 4):S25-S30
16. de Paula Soares V, Zangrossi H Jr (2004) Involvement of 5-HT1A and 5-HT2 receptors of the dorsal periaqueductal gray in the regulation of the defensive behaviors generated by the elevated T-maze. Brain Res Bull 64(2):181-188
17. Eriksson E, Carlsson M, Nilsson C, Soderpalm B (1986) Does alprazolam, in contrast to diazepam, activate alpha 2-adrenoceptors involved in the regulation of rat growth hormone secretion? Life Sci 38(16):1491-1498
18. Fawcett JA, Kravitz HM (1982) Alprazolam: pharmacokinetics, clinical efficacy, and mechanism of action. Pharmacotherapy 2(5):243-254
19. Glennon RA, Metwally K, Dukat M, Ismaiel AM, De los Angeles J, Herndon J, Teitler M, Khorana N (2002) Ketanserin and spiperone as templates for novel serotonin 5-HT(2A) antagonists. Curr Top Med Chem 2(6):539-558
20. Gorman JM, Liebowitz MR, Fyer AJ, Stein J (1989) A neuroanatomical hypothesis for panic disorder. Am J Psychiatry 146(2):148-161
21. Graeff FG (1990) Brain defense systems and anxiety. In: Roth M, Burrows GD, Noyes R (eds) Handbook of anxiety. The neurobiology of anxiety. Elsevier, Amsterdam, pp 307-354
22. Graeff FG (2004) Serotonin, the periaqueductal gray and panic. Neurosci Biobehav Rev 28(3):239-259
23. Graeff FG, Zangrossi H Jr (2002) Animal models of anxiety disorders. In: D'Haenen H, den Boer JA, Westenberg H, Willner P (eds) Textbook of biological psychiatry. Wiley, London, pp 879-893
24. Graeff FG, Silveira MC, Nogueira RL, Audi EA, Oliveira RM (1993) Role of the amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res 58:123-131
25. Griebel G, Blanchard DC, Jung A, Lee JC, Masuda CK, Blanchard RJ (1995) Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam. Neuropharmacology 34(12):1625-1633
26. Hensler JG (2003) Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci 72(15):1665-1682
27. Hjorth S, Bengtsson HJ, Kullberg A, Carlzon D, Peilot H, Auerbach SB (2000) Serotonin autoreceptor function and antidepressant drug action. J Psychopharmacol 14(2):177-185
28. Jacob CA, Cabral AH, Almeida LP, Magierek V, Ramos PL, Zanoveli JM, Landeira-Fernandez J, Zangrossi Jr H, Nogueira RL (2002) Chronic imipramine enhances 5-HT(1A) and 5-HT(2) receptors-mediated inhibition of panic-like behavior in the rat dorsal periaqueductal gray. Pharmacol Biochem Behav 72:761-766
29. Jenck F, Moreau JL, Martin JR (1995) Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res 57:181-191
30. Jenck F, Moreau JL, Berendsen HH, Boes M, Broekkamp CL, Martin JR, Wichmann J, Van Delft AM (1998) Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol 8:161-168
31. Joordens RJ, Hijzen TH, Olivier B (1998) The anxiolytic effect on the fear-potentiated startle is not due to a non-specific disruption. Life Sci 63(25):2227-2232
32. Kasper S, Resinger E (2001) Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol 11(4):307-321
33. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE (2006) The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry 63:415-424
34. King CM, Gommans J, Joordens RJ, Hijzen TH, Maes RA, Olivier B (1997) Effects of 5-HT1A receptor ligands in a modified Geller-Seifter conflict model in the rat. Eur J Pharmacol 325(2-3):121-128
35. Klein DF, Fink M (1962) Psychiatric reaction patterns to imipramine. Am J Psychiatry 119:432-438
36. Klein E, Zinder O, Colin V, Zilberman I, Levy N, Greenberg A, Lenox RH (1995) Clinical similarity and biological diversity in the response to alprazolam in patients with panic disorder and generalized anxiety disorder. Acta Psychiatr Scand 92(6):399-408
37. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M (2004) Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol 370(2):114-123
38. Kravitz HM, Fawcett J, Newman AJ (1993) Alprazolam and depression: a review of risks and benefits. J Clin Psychiatry 54(Suppl):78-84
39. Lader M (2005) Management of panic disorder. Expert Rev Neurother 5(2):259-266
40. Lovick TA (2000) Panic disorder - a malfunction of multiple transmitter control systems within the midbrain periaqueductal gray matter. Neuroscientist 6:48-59
41. Marseillan RF (1977) A solid state sine-wave stimulator. Physiol Behav 19:339-340
42. Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70(2):83-244
43. Millan MJ, Lejeune F, Gobert A (2000) Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 14(2):114-138
44. Mongeau R, Marsden CA (1997) Effect of imipramine treatments on the 5-HT1A-receptor-mediated inhibition of panic-like behaviours in rats. Psychopharmacology 131:321-328
45. Mongeau R, de Montigny C, Blier P (1994) Electrophysiologic evidence for desensitization of alpha 2-adrenoceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration. Neuropsychopharmacology 10:41-51
46. Mongeau R, Weiss M, de Montigny C, Blier P (1998) Effect of acute, short- and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons. Neuropharmacology 37(7):905-918
47. Moroz G (2004) High-potency benzodiazepines: recent clinical results. J Clin Psychiatry 65(Suppl 5):13-18
48. Nashold BS Jr, Wilson WP, Slaughter DG (1969) Sensations evoked by stimulation in the midbrain of man. J Neurosurg 30:14-24
49. Nogueira RL, Graeff FG (1995) Role of 5-HT receptor subtypes in the modulation of dorsal periaqueductal gray generated aversion. Pharmacol Biochem Behav 52:1-6
50. Olds ME, Olds J (1962) Approach-escape interactions in rat brain. Am J Physiol 203:803-810
51. Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates 3rd edn. Academic, San Diego
52. Pecknold JC (1997) A risk-benefit assessment of buspirone in the treatment of anxiety disorders. Drug Saf 16(2):118-132
53. Petty F, Trivedi MH, Fulton M, Rush AJ (1995) Benzodiazepines as antidepressants: does GABA play a role in depression? Biol Psychiatry 38(9):578-591
54. Schenberg LC, Bittencourt AS, Sudre EC, Vargas LC (2001) Modeling panic attacks. Neurosci Biobehav Rev 25:647-659
55. Schütz MT, de Aguiar JC, Graeff FG (1985) Anti-aversive role of serotonin in the dorsal periaqueductal grey matter. Psychopharmacology 85:340-345
56. Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E (1993) The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 88:1-11
57. Soderpalm B (1987) Pharmacology of the benzodiazepines; with special emphasis on alprazolam. Acta Psychiatr Scand Suppl 335:39-46
58. Susman J, Klee B (2005) The role of high-potency benzodiazepines in the treatment of panic disorder. Prim Care Companion J Clin Psychiat 7:5-11
59. Svensson TH, Bunney BS, Aghajanian GK (1975) Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res 92(2):291-306
60. Tanay VM, Greenshaw AJ, Baker GB, Bateson AN (2001) Common effects of chronically administered antipanic drugs on brainstem GABA(A) receptor subunit gene expression. Mol Psychiatry 6(4):404-412
61. Thomas DR, Gittins SA, Collin LL, Middlemiss DN, Riley G, Hagan J, Gloger I, Ellis CE, Forbes IT, Brown AM (1998) Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719. Br J Pharmacol 124(6):1300-1306
62. van Vliet IM, den Boer JA, Westenberg HG, Slaap BR (1996) A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. J Clin Psychopharmacol 16(4):299-306
63. Zanoveli JM, Nogueira RL, Zangrossi H Jr (2005) Chronic imipramine treatment sensitizes 5-HT1A and 5-HT2A receptors in the dorsal periaqueductal gray matter: evidence from the elevated T-maze test of anxiety. Behav Pharmacol 16(7):543-552
64. Zanoveli JM, Nogueira RL, Zangrossi H Jr (2007) Enhanced reactivity of 5-HT1A receptors in the rat dorsal periaqueductal gray matter after chronic treatment with fluoxetine and sertraline: evidence from the elevated T-maze. Neuropharmacology 52(4):1188-1195